JP2021526512A5 - - Google Patents
Info
- Publication number
- JP2021526512A5 JP2021526512A5 JP2020564514A JP2020564514A JP2021526512A5 JP 2021526512 A5 JP2021526512 A5 JP 2021526512A5 JP 2020564514 A JP2020564514 A JP 2020564514A JP 2020564514 A JP2020564514 A JP 2020564514A JP 2021526512 A5 JP2021526512 A5 JP 2021526512A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- approximately
- antibody
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024025646A JP2024059805A (ja) | 2018-05-16 | 2024-02-22 | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672222P | 2018-05-16 | 2018-05-16 | |
| US62/672,222 | 2018-05-16 | ||
| US201862736804P | 2018-09-26 | 2018-09-26 | |
| US62/736,804 | 2018-09-26 | ||
| US201962842080P | 2019-05-02 | 2019-05-02 | |
| US62/842,080 | 2019-05-02 | ||
| PCT/IB2019/054034 WO2019220369A2 (en) | 2018-05-16 | 2019-05-15 | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024025646A Division JP2024059805A (ja) | 2018-05-16 | 2024-02-22 | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021526512A JP2021526512A (ja) | 2021-10-07 |
| JP2021526512A5 true JP2021526512A5 (enExample) | 2022-08-15 |
| JP7444790B2 JP7444790B2 (ja) | 2024-03-06 |
Family
ID=67253932
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564514A Active JP7444790B2 (ja) | 2018-05-16 | 2019-05-15 | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
| JP2020564662A Active JP7395508B2 (ja) | 2018-05-16 | 2019-05-15 | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
| JP2023201165A Active JP7749643B2 (ja) | 2018-05-16 | 2023-11-29 | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
| JP2024025646A Pending JP2024059805A (ja) | 2018-05-16 | 2024-02-22 | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
| JP2025157772A Pending JP2026009121A (ja) | 2018-05-16 | 2025-09-24 | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564662A Active JP7395508B2 (ja) | 2018-05-16 | 2019-05-15 | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
| JP2023201165A Active JP7749643B2 (ja) | 2018-05-16 | 2023-11-29 | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
| JP2024025646A Pending JP2024059805A (ja) | 2018-05-16 | 2024-02-22 | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
| JP2025157772A Pending JP2026009121A (ja) | 2018-05-16 | 2025-09-24 | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US12065500B2 (enExample) |
| EP (2) | EP3793599A1 (enExample) |
| JP (5) | JP7444790B2 (enExample) |
| KR (2) | KR20220080044A (enExample) |
| CN (3) | CN113164588A (enExample) |
| AU (4) | AU2019270623B2 (enExample) |
| BR (2) | BR112020023187A2 (enExample) |
| CA (2) | CA3100118A1 (enExample) |
| CL (3) | CL2020002945A1 (enExample) |
| DO (1) | DOP2020000209A (enExample) |
| IL (2) | IL278667B2 (enExample) |
| JO (1) | JOP20200292A1 (enExample) |
| MA (2) | MA52640A (enExample) |
| MX (5) | MX2020012270A (enExample) |
| MY (2) | MY203469A (enExample) |
| PH (2) | PH12020551908A1 (enExample) |
| SG (2) | SG11202010977QA (enExample) |
| TW (4) | TW202438109A (enExample) |
| UA (1) | UA130542C2 (enExample) |
| UY (2) | UY38236A (enExample) |
| WO (2) | WO2019220368A1 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| CN109134658B (zh) | 2011-10-31 | 2022-10-14 | 中外制药株式会社 | 控制了重链与轻链的缔合的抗原结合分子 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| AU2015244814B2 (en) | 2014-04-07 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| MX2016014434A (es) | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
| CN107406506A (zh) | 2014-12-04 | 2017-11-28 | 詹森生物科技公司 | 用于治疗急性髓系白血病的抗cd38抗体 |
| EA201792546A1 (ru) | 2015-05-20 | 2018-04-30 | Янссен Байотек, Инк. | Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей |
| US10738118B2 (en) | 2015-05-29 | 2020-08-11 | Amphivena Therapeutics, Inc. | Methods of using bispecific CD33 and CD3 binding proteins |
| CA3004152C (en) | 2015-11-03 | 2024-04-16 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| UA130542C2 (uk) | 2018-05-16 | 2026-03-18 | Янссен Байотек, Інк. | Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта |
| CA3101271A1 (en) * | 2018-05-24 | 2019-11-28 | Janssen Biotech, Inc. | Anti-cd3 antibodies and uses thereof |
| MA52772A (fr) * | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations |
| PE20211916A1 (es) * | 2018-05-24 | 2021-09-28 | Janssen Biotech Inc | Agentes aglutinantes del psma y usos de estos |
| US11591395B2 (en) * | 2019-04-19 | 2023-02-28 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti-PSMA/CD3 antibody |
| EP3733707A1 (en) * | 2019-04-30 | 2020-11-04 | Celyad S.A. | Car t-cells targeting bcma and uses thereof |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| MX2022000111A (es) | 2019-07-10 | 2022-02-10 | Chugai Pharmaceutical Co Ltd | Moleculas de union a claudina-6 y usos de las mismas. |
| CA3248329A1 (en) * | 2019-07-31 | 2025-11-29 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
| MX2022001711A (es) * | 2019-08-09 | 2022-05-10 | A2 Biotherapeutics Inc | Receptores en la superficie celular que responden a la perdida de heterocigosidad. |
| JP7773466B2 (ja) * | 2019-11-26 | 2025-11-19 | シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド | Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
| IL296358A (en) * | 2020-03-13 | 2022-11-01 | Janssen Biotech Inc | Materials and methods for modulating delta chain mediated immunity |
| JP2023524875A (ja) * | 2020-05-11 | 2023-06-13 | ヤンセン バイオテツク，インコーポレーテツド | 多発性骨髄腫を治療するための方法 |
| BR112022021956A2 (pt) * | 2020-05-13 | 2022-12-13 | Pfizer | Métodos, terapias e usos para o tratamento de câncer |
| BR112022023392A2 (pt) * | 2020-05-19 | 2022-12-20 | Janssen Biotech Inc | Composições que compreendem um agente terapêutico de redirecionamento de células t e um inibidor da via de adesão de vla-4 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| CN116249714A (zh) | 2020-05-27 | 2023-06-09 | 詹森生物科技公司 | 包含cd3抗原结合结构域的蛋白质及其用途 |
| AU2021282817B2 (en) * | 2020-06-01 | 2025-07-03 | Mustbio Co., Ltd. | Bispecific antibody or antigen-binding fragment thereof, and preparation method therefor |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| EP4213945A1 (en) * | 2020-09-16 | 2023-07-26 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| CA3199319A1 (en) * | 2020-10-22 | 2022-04-28 | Janssen Biotech, Inc. | Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses |
| EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| JP2024507180A (ja) * | 2021-02-16 | 2024-02-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体 |
| US20250074996A1 (en) * | 2021-02-19 | 2025-03-06 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF |
| CN117715647A (zh) * | 2021-04-08 | 2024-03-15 | 埃迪瓦生物治疗公司 | 用nk细胞和cd38靶向抗体治疗癌症 |
| KR20240008345A (ko) * | 2021-05-18 | 2024-01-18 | 얀센 바이오테크 인코포레이티드 | T 세포 재유도 치료제 및 항-cd44 치료제를 포함하는 조성물 |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| EP4347039A1 (en) * | 2021-05-28 | 2024-04-10 | Janssen Biotech, Inc. | Bcma as a target for t cell redirecting antibodies in b cell lymphomas |
| CN115521381B (zh) * | 2021-06-24 | 2024-10-29 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
| WO2023284806A1 (zh) * | 2021-07-14 | 2023-01-19 | 江苏恒瑞医药股份有限公司 | 特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途 |
| EP4426436A4 (en) * | 2021-11-03 | 2025-09-03 | Janssen Biotech Inc | METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC GPRC5DXCD3 ANTIBODIES |
| MX2024005392A (es) * | 2021-11-03 | 2024-08-06 | Janssen Biotech Inc | Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3. |
| KR20240099432A (ko) * | 2021-11-10 | 2024-06-28 | 얀센 바이오테크 인코포레이티드 | 이중특이성 bcma/cd3 항체를 포함하는 안정한 제형 |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| US20240228650A9 (en) * | 2022-05-06 | 2024-07-11 | Ichnos Sciences SA | CD3/BCMA/CD38 Trispecific Antibodies |
| CN119278217A (zh) * | 2022-05-27 | 2025-01-07 | 德琪(杭州)生物有限公司 | 新型抗gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子以及其用途 |
| CN114807358B (zh) * | 2022-05-30 | 2023-02-28 | 北京体育大学 | 一种与肌腱损伤相关的生物标志物 |
| IL317463A (en) | 2022-06-06 | 2025-02-01 | Shandong Simcere Biopharmaceutical Co Ltd | Multispecific antibodies targeting BCMA, GPRC5D and T cells and their application |
| WO2024052831A1 (en) * | 2022-09-09 | 2024-03-14 | Janssen Biotech, Inc. | Method of treating cancer with an anti tmeff2xcd3 bispecific antibody |
| CN117924485A (zh) * | 2022-10-25 | 2024-04-26 | 上海祥耀生物科技有限责任公司 | 一种抗gprc5d的多特异性抗体 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024114676A1 (zh) | 2022-11-29 | 2024-06-06 | 江苏恒瑞医药股份有限公司 | Cldn18.2/4-1bb结合蛋白及其医药用途 |
| WO2024146458A1 (zh) * | 2023-01-06 | 2024-07-11 | 广东东阳光药业股份有限公司 | 抗il-11细胞因子人源化抗体 |
| TW202434644A (zh) | 2023-02-07 | 2024-09-01 | 大陸商上海齊魯製藥研究中心有限公司 | 三特異性抗原結合分子及其應用 |
| CN120857940A (zh) | 2023-02-17 | 2025-10-28 | 瑞泽恩制药公司 | 对cd3/taa双特异性抗体有反应的诱导型nk细胞 |
| EP4698192A2 (en) * | 2023-04-18 | 2026-02-25 | Hackensack Meridian Health, Inc. | Methods for targeted immunotherapy of acute myeloid leukemia (aml) |
| CA3205511A1 (en) * | 2023-04-19 | 2025-03-17 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| US20250242019A2 (en) * | 2023-04-19 | 2025-07-31 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| AU2024257950A1 (en) * | 2023-04-19 | 2025-12-04 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| WO2025059362A1 (en) * | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025096717A1 (en) | 2023-11-01 | 2025-05-08 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| WO2025094107A1 (en) | 2023-11-01 | 2025-05-08 | Janssen Biotech, Inc. | Methods for treating high-risk smoldering multiple myeloma |
| WO2025229160A1 (en) * | 2024-05-01 | 2025-11-06 | Commit Biologics Aps | Engineered proteins that engage complement factor and a protein antigen, methods, and uses thereof |
| WO2025243241A1 (en) | 2024-05-23 | 2025-11-27 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| WO2026033437A1 (en) | 2024-08-07 | 2026-02-12 | Janssen Biotech, Inc. | Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics |
| WO2026078659A1 (en) * | 2024-10-11 | 2026-04-16 | Janssen Biotech, Inc. | Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| PT1015576E (pt) | 1997-09-16 | 2005-09-30 | Egea Biosciences Llc | Metodo para a sintese quimica completa e montagem de genes e de genomas |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| US7902338B2 (en) * | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| WO2008037257A2 (en) | 2006-09-26 | 2008-04-03 | Genmab A/S | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| DK2352763T4 (da) | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| US20110293619A1 (en) | 2008-10-01 | 2011-12-01 | Micromet Ag | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY |
| ES2705714T3 (es) | 2008-10-31 | 2019-03-26 | Janssen Biotech Inc | Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones |
| BRPI1008532B1 (pt) | 2009-02-12 | 2021-12-14 | Janssen Biotech, Inc | Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| AR085934A1 (es) | 2011-04-08 | 2013-11-06 | Ab Science | Tratamiento de mieloma multiple con masitinib |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| KR101317809B1 (ko) * | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| UA118255C2 (uk) | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| PT2931030T (pt) | 2012-12-14 | 2020-08-03 | Open Monoclonal Tech Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| HK1221908A1 (zh) * | 2013-04-29 | 2017-06-16 | Adimab, Llc | 多特异(polyspecificity)试剂，其制备方法和用途 |
| ES2825625T3 (es) | 2013-10-31 | 2021-05-17 | Sanofi Sa | Anticuerpos anti-CD38 específicos para tratar cánceres humanos |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| MX2016014434A (es) | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
| MA40609B1 (fr) | 2014-09-05 | 2020-05-29 | Janssen Pharmaceutica Nv | Agents de liaison cd123 et leurs utilisations |
| BR112017011932A8 (pt) | 2014-12-05 | 2022-11-08 | Memorial Sloan Kettering Cancer Center | Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso |
| CN118271463A (zh) * | 2014-12-05 | 2024-07-02 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的嵌合抗原受体及其用途 |
| DK3303396T5 (da) | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| MX2018002043A (es) * | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| CA3004152C (en) | 2015-11-03 | 2024-04-16 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| JOP20170017B1 (ar) * | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| KR102331061B1 (ko) | 2016-08-22 | 2021-11-25 | 스미토모덴키고교가부시키가이샤 | 경질 재료 및 절삭 공구 |
| US10882918B2 (en) | 2016-09-30 | 2021-01-05 | Hoffmann-La Roche Inc. | Bispecific T cell activating antigen binding molecules |
| JP7267914B2 (ja) | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| SG11201907321TA (en) | 2017-02-07 | 2019-09-27 | Daiichi Sankyo Co Ltd | Anti-gprc5d antibody and molecule comprising the antibody |
| WO2018187215A1 (en) | 2017-04-03 | 2018-10-11 | Merrimack Pharmaceuticals, Inc. | Bispecific 4-1bb agonist molecules |
| KR102820804B1 (ko) | 2017-09-22 | 2025-06-16 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체 |
| UA130542C2 (uk) | 2018-05-16 | 2026-03-18 | Янссен Байотек, Інк. | Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта |
| WO2024044545A1 (en) * | 2022-08-23 | 2024-02-29 | Janssen Biotech, Inc. | Approved products for the treatment of multiple myeloma |
-
2019
- 2019-05-15 UA UAA202008019A patent/UA130542C2/uk unknown
- 2019-05-15 IL IL278667A patent/IL278667B2/en unknown
- 2019-05-15 MY MYPI2020005950A patent/MY203469A/en unknown
- 2019-05-15 CN CN201980047683.7A patent/CN113164588A/zh active Pending
- 2019-05-15 MA MA052640A patent/MA52640A/fr unknown
- 2019-05-15 MY MYPI2020005944A patent/MY205856A/en unknown
- 2019-05-15 JP JP2020564514A patent/JP7444790B2/ja active Active
- 2019-05-15 CA CA3100118A patent/CA3100118A1/en active Pending
- 2019-05-15 EP EP19739378.8A patent/EP3793599A1/en active Pending
- 2019-05-15 JP JP2020564662A patent/JP7395508B2/ja active Active
- 2019-05-15 KR KR1020207036215A patent/KR20220080044A/ko not_active Ceased
- 2019-05-15 SG SG11202010977QA patent/SG11202010977QA/en unknown
- 2019-05-15 KR KR1020207035911A patent/KR20210011002A/ko active Pending
- 2019-05-15 WO PCT/IB2019/054033 patent/WO2019220368A1/en not_active Ceased
- 2019-05-15 BR BR112020023187-8A patent/BR112020023187A2/pt unknown
- 2019-05-15 US US16/412,701 patent/US12065500B2/en active Active
- 2019-05-15 MA MA052632A patent/MA52632A/fr unknown
- 2019-05-15 JO JOP/2020/0292A patent/JOP20200292A1/ar unknown
- 2019-05-15 AU AU2019270623A patent/AU2019270623B2/en active Active
- 2019-05-15 MX MX2020012270A patent/MX2020012270A/es unknown
- 2019-05-15 CA CA3100157A patent/CA3100157A1/en active Pending
- 2019-05-15 BR BR112020023264-5A patent/BR112020023264A2/pt unknown
- 2019-05-15 WO PCT/IB2019/054034 patent/WO2019220369A2/en not_active Ceased
- 2019-05-15 US US16/412,831 patent/US12012461B2/en active Active
- 2019-05-15 CN CN201980038160.6A patent/CN112368019B/zh active Active
- 2019-05-15 EP EP19803950.5A patent/EP3793606B1/en active Active
- 2019-05-15 MX MX2020012286A patent/MX2020012286A/es unknown
- 2019-05-15 AU AU2019270624A patent/AU2019270624B2/en active Active
- 2019-05-15 SG SG11202011306TA patent/SG11202011306TA/en unknown
- 2019-05-15 CN CN202510203084.7A patent/CN120285175A/zh active Pending
- 2019-05-16 TW TW113121609A patent/TW202438109A/zh unknown
- 2019-05-16 UY UY0001038236A patent/UY38236A/es unknown
- 2019-05-16 UY UY0001038235A patent/UY38235A/es not_active Application Discontinuation
- 2019-05-16 TW TW108116951A patent/TWI901569B/zh active
- 2019-05-16 TW TW113109635A patent/TW202430571A/zh unknown
- 2019-05-16 TW TW108116950A patent/TWI899054B/zh active
-
2020
- 2020-11-09 PH PH12020551908A patent/PH12020551908A1/en unknown
- 2020-11-12 CL CL2020002945A patent/CL2020002945A1/es unknown
- 2020-11-13 MX MX2024013523A patent/MX2024013523A/es unknown
- 2020-11-13 MX MX2024013525A patent/MX2024013525A/es unknown
- 2020-11-13 MX MX2024013526A patent/MX2024013526A/es unknown
- 2020-11-13 PH PH12020551932A patent/PH12020551932A1/en unknown
- 2020-11-13 DO DO2020000209A patent/DOP2020000209A/es unknown
-
2021
- 2021-08-27 CL CL2021002267A patent/CL2021002267A1/es unknown
-
2023
- 2023-06-12 US US18/208,361 patent/US20240101697A1/en active Pending
- 2023-11-29 JP JP2023201165A patent/JP7749643B2/ja active Active
- 2023-11-29 AU AU2023274132A patent/AU2023274132A1/en active Pending
-
2024
- 2024-02-22 JP JP2024025646A patent/JP2024059805A/ja active Pending
- 2024-04-10 AU AU2024202300A patent/AU2024202300A1/en active Pending
- 2024-05-07 US US18/657,180 patent/US20240301083A1/en active Pending
- 2024-05-29 CL CL2024001607A patent/CL2024001607A1/es unknown
-
2025
- 2025-09-24 JP JP2025157772A patent/JP2026009121A/ja active Pending
- 2025-10-22 IL IL324145A patent/IL324145A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526512A5 (enExample) | ||
| US11718681B2 (en) | Anti-SIRP α antibodies | |
| US20250109211A1 (en) | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies | |
| JP2021526136A5 (enExample) | ||
| JP2022542450A5 (enExample) | ||
| JP2021525087A (ja) | 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体および使用方法 | |
| JP2021525082A5 (enExample) | ||
| JP2018520101A5 (enExample) | ||
| CN111148761A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2021520832A (ja) | キレート化された放射性核種に対する抗体 | |
| JP2024509018A5 (enExample) | ||
| JP2024515396A5 (enExample) | ||
| JP2022534212A5 (enExample) | ||
| JP2023547506A5 (enExample) | ||
| JP2023517660A5 (enExample) | ||
| CN115197325A (zh) | 抗体在抗肿瘤治疗中的用途 | |
| WO2024113099A1 (en) | Protease cleavable recombinant bispecific antibodies and compositions and uses thereof | |
| US20250215087A1 (en) | Combination therapy of kras inhibitor and treg depleting agent | |
| US20230295292A1 (en) | Methods of treating cancers and enhancing efficacy of gprc5dxcd3 bispecific antibodies | |
| NZ805741A (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
| NZ769788A (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
| NZ769788B2 (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
| CN118615438A (zh) | 包含抗ctla4-抗pd-1双特异性抗体的药物组合及其用途 | |
| HK40114665A (zh) | 包含抗ctla4-抗pd-1双特异性抗体的药物组合及其用途 | |
| AU2024330072A1 (en) | Masked il-2 cytokines and methods of use thereof |